Showing results (791-800 of 6,303) with videos related to

Sort By:
Pageof 631
Diabetes, Obesity & Metabolism|February 11, 2020
Cost-effectiveness of dapagliflozin as an adjunct to insulin for the treatment of type 1 diabetes mellitus in the United KingdomHayley Bennett, Amarjeet Tank, Marc Evans, et al.
Diabetes, Obesity & Metabolism|February 14, 2020
Efficacy and safety of dual add-on therapy with dapagliflozin plus saxagliptin versus glimepiride in patients with poorly controlled type 2 diabetes on a stable dose of metformin: Results from a 52-week, randomized, active-controlled trialJuan P Frias, Guillermo Gonzalez-Galvez, Eva Johnsson, et al.
Diabetes, Obesity & Metabolism|February 14, 2020
Brain free fatty acid uptake is elevated in morbid obesity, and is irreversible 6 months after bariatric surgery: A positron emission tomography studyEleni Rebelos, Jussi Hirvonen, Marco Bucci, et al.
Diabetes, Obesity & Metabolism|November 7, 2019
Efficacy and safety of MYL-1501D versus insulin glargine in people with type 1 diabetes mellitus: Results of the INSTRIDE 3 phase 3 switch studyThomas C Blevins, Abhijit Barve, Yaron Raiter, et al.
Diabetes, Obesity & Metabolism|November 7, 2019
Efficacy and safety of empagliflozin as add-on to insulin in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trialHirohito Sone, Tatsuroh Kaneko, Kosuke Shiki, et al.
Diabetes, Obesity & Metabolism|November 7, 2019
Role of endogenous glucagon-like peptide-1 enhanced by vildagliptin in the glycaemic and energy expenditure responses to intraduodenal fat infusion in type 2 diabetesCong Xie, Xuyi Wang, Karen L Jones, et al.
Diabetes, Obesity & Metabolism|January 10, 2020
Interplay of adenosine monophosphate-activated protein kinase/sirtuin-1 activation and sodium influx inhibition mediates the renal benefits of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: A novel conceptual frameworkMilton Packer
Diabetes, Obesity & Metabolism|February 14, 2019
Glycaemic control after treatment intensification in patients with type 2 diabetes uncontrolled on two or more non-insulin antidiabetic drugs in a real-world settingSilvia Canivell, Manel Mata-Cases, Jordi Real, et al.
Diabetes, Obesity & Metabolism|November 27, 2018
Exenatide use and incidence of pancreatic and thyroid cancer: A retrospective cohort studyCaihua Liang, Monica L Bertoia, Yan Ding, et al.
Diabetes, Obesity & Metabolism|December 8, 2018
Metabolic and proteomic signatures of hypoglycaemia in type 2 diabetesAnna Halama, Hassan Kahal, Aditya M Bhagwat, et al.
Pageof 631